Akebia Therapeutics, Inc. AKBA
Set alert
0.71 USD 0.00 +0.27%
At close · Nov 2
0.71 0.00 0.00%
After hours · Nov 2, 6:49 PM ET
0.692 Day range 0.73
0.542 52-week range 2.22
- YTD
- -56.00%
- 1 year
- -67.95%
- Open
- 0.71
- Prev close
- 0.7065
- Mkt cap
- 196.30M
- Vol
- 4.82M
- Avg vol
- 7.84M
- EPS
- -0.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.692
- High
- 0.73
- Forward P/E
- -7.15
- Beta
- 0.73
- Short ratio
- 4.71
- Inst. own
- 27.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.80
- 200-d avg
- 1.45
- 1y target
- 5.50
5Y chart
Events in this range
- Mar 28, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Sep 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 10, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 23, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 8, 2025Earnings: 0.03; estimate —; surprise 200%
Signals (83)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| RSI: Oversold | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| RSI: Oversold | Jan 12, 2026 | 9 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| RSI: Overbought | Jul 7, 2025 | 1 year ago |
| RSI: Overbought | Jun 16, 2025 | 1 year ago |
| RSI: Overbought | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 17, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Feb 19, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 21, 2023 | 3 years ago |
| RSI: Overbought | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 17, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Apr 24, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 24, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 27, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| RSI: Overbought | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| RSI: Oversold | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | Mar 28, 2022 | 4 years ago |
| RSI: Oversold | Mar 28, 2022 | 4 years ago |
| SMA: Bullish | Feb 21, 2022 | 4 years ago |
Key statistics
- Market cap
- 405.82M
- Enterprise value
- 468.45M
- Trailing P/E
- 0.00
- Forward P/E
- -7.15
- PEG ratio
- 0.00
- Price / sales
- 2.39
- Price / book
- 0.00
- EPS (TTM)
- -0.22
- Beta
- 0.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -27.07%
- Revenue (TTM)
- 169.88M
- Revenue growth
- -11.00%
- Free cash flow
- 8.98M
- Total cash
- 34.02M
- Total debt
- 103.20M
- Return on equity
- 0.00%
- Shares outstanding
- 218.18M
- Short % of float
- 5.35%
- 50-day average
- 1.80
- 200-day average
- 1.45
Analyst view
Consensus: none
Price target (mean) 5.50 +676.4% upside
Now 0.7084
- Target (low)
- 4.00
- Target (mean)
- 5.50
- Target (high)
- 7.50
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.04.
Financials — quick view
AKBA Revenue — quarterly 49.13M
AKBA Net income — quarterly -8.91M
AKBA EPS — quarterly -0.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 8, 2025 | Mar 1, 2025 | — | 0.03 | +0.06 | +200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 28, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- akebia.com
News
- Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
- U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
- Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
- Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
- Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
- Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Your note
Sign in to keep a note on AKBA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ADRIAN | Director | Stock Award(Grant) | Jun 5, 2024 | 164,800 |
| DAHAN MICHEL | Chief Operating Officer | Sale | May 12, 2024 | 672,092 |
| FRIESON RON | Director | Stock Award(Grant) | Jun 5, 2024 | 73,700 |
| GILMAN STEVEN C | Director | Stock Award(Grant) | Jun 5, 2024 | 117,130 |
| HADAS NICOLE R | Officer | Sale | May 12, 2024 | 651,243 |
| OSTROWSKI ERIK | Chief Financial Officer | Stock Award(Grant) | Jun 27, 2024 | 350,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.97% | 15,197,207 | 28.27M | Sep 29, 2024 |
| Vanguard Group Inc | 4.62% | 10,070,298 | 18.73M | Sep 29, 2024 |
| Alerce Investment Management, L.P. | 2.63% | 5,747,906 | 10.69M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.18% | 4,754,464 | 8.84M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.70% | 3,717,800 | 6.92M | Sep 29, 2024 |
| State Street Corporation | 1.57% | 3,430,527 | 6.38M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.72% | 5,945,188 | 11.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.53% | 5,530,325 | 10.29M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 2,602,859 | 4.84M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.98% | 2,132,609 | 3.97M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.81% | 1,775,159 | 3.30M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 1,083,041 | 2.01M | Oct 30, 2024 |